

- Sub E1
31. (Amended) The fusion immunotoxin according to claim 30, wherein the toxin moiety is DT390.
32. (Amended) The fusion immunotoxin according to claim 31, comprising DT390 linked via its carboxy terminus, optionally via a linker, to the single chain variable region of the anti-CD3 antibody.
33. (Amended) The fusion immunotoxin according to claim 32, wherein the single chain variable region of the anti-CD3 antibody comprises the variable light domain linked via its carboxy terminus to the variable heavy domain, optionally via a linker.
- 

- Sub E2
38. (Amended) A method for inhibiting rejection of transplanted tissue or organs, comprising administering to a subject in need thereof an immunotoxin according to claim 30.
39. (Amended) A method for treating an autoimmune disease, comprising administering to a subject in need thereof an immunotoxin according to claim 30.
40. (Amended) A method of treating T cell leukemias or lymphomas, comprising administering to a subject in need thereof an immunotoxin according to claim 30.
41. (Amended) A method of treating graft-versus-host disease, comprising administering to a subject in need thereof an immunotoxin according to claim 30.